Pfizer Venture Investments (PVI), the venture capital arm of Pfizer, Inc, was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. PVI seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing compounds and technologies that have the potential to enhance Pfizer’s pipeline and shape the future of our industry.
With a $50M annual budget for private investments, PVI may invest up to $10M per round in selected companies in any stage of development, with a strong focus on growth stage opportunities. Other investments, including fund investing, spinout opportunities, and PIPEs will also be considered as appropriate. We actively manage our current portfolio and are seeking to make new investments.
We consider investments in a broad array of healthcare related areas, including therapeutics, platform technologies, diagnostics, drug delivery, pharmaceutical services, healthcare IT, and other technologies impacting drug discovery and development. We will consider companies at all stages of development, including start-ups, spinouts, and consortia investments. While primarily U.S. focused, international investments may represent up to 20% of the portfolio. We have the ability to lead or join a syndicate of investors and will seek board representation as appropriate.
- Active investor – work with management to build shareholder value, assist in product strategy development, and facilitate business development relationships with Pfizer
- Ability to utilize the broad network and specialized expertise of Pfizer and its many divisions, contacts, and data sources to benefit portfolio companies
- Simple, streamlined approval process for most investment decisions
- Potential for Pfizer partnership opportunity and access to large Pharma perspective and pedigree are added to portfolio company’s assets
Our Team Is Looking Forward to Working With You